IRVINE, Calif.— Allergan, Inc. (NYSE: AGN) reported total product net sales of $1,889.0 million for the quarter ended Dec. 31, 2014, an increase of 13.8 percent increase, or 17.2 percent on a constant currency basis, compared to total product net sales in the fourth quarter of 2013.

Total specialty pharmaceuticals net sales increased 12.4 percent, or 15.3 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2013. Total core medical devices net sales increased 20.7 percent, or 26.9 percent on a constant currency basis, compared to total core medical devices net sales in the fourth quarter of 2013.

For the fourth quarter of 2014, Allergan recorded the strongest increase in absolute dollar sales in any quarter in its history. The gains were driven by exceptional performance across all of Allergan’s businesses and geographic regions, the company said in a statement.

“This is a tribute to the focus of our employees during the unsolicited acquisition attempt,” said David E.I. Pyott, Allergan’s chairman of the board and CEO. “Furthermore, we are excited about the acquisition by Actavis, with the vision of creating the most dynamic company in a new category of Growth Pharma companies.”

For the full year ended Dec. 31, 2014, Allergan posted the greatest absolute dollar sales growth of over $1 billion on a constant currency basis, a record in its 66-year corporate history. Operating cash flow after capital expenditures was approximately $1.7 billion.

Vision Monday reported that on Nov.17, 2014, Actavis (NYSE: ACT) and Allergan announced that they had entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock.